Incidence and Clinical Outcomes of Febrile Neutropenia in Adult Cancer Patients with Chemotherapy Using Korean Nationwide Health Insurance Database
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The aim of this study was to evaluate the episodes of febrile neutropenia (FN) in patients with gastric cancer (GC),colorectal cancer (CRC), lung cancer (LC), and breast cancer (BC); and to identify the incidence and trends of admission rates, aswell as factors affecting mortality. Materials and Methods: Using nationwide claims data, all new admissions to hospitals for FN were selected. We evaluated theincidence of FN and mortality-related clinical factors in adult cancer patients who received cytotoxic chemotherapy from January2004 to December 2013. Results: While the incidence of FN increased, the length of hospitalization decreased in Korea. The incidence of FN was 19.8% inLC patients, 15.5% in GC patients, 13.3% in BC patients, and 9.5% in CRC patients. The overall in-hospital mortality of FN was12.9% and showed a decreasing trend. Admission rates to intensive care units and in-hospital mortality were the highest for lungcancer (15.2% and 19.3%, respectively). Age and sepsis syndrome were risk factors for in-hospital mortality for all cancer types. Conclusion: Careful observation and active prophylaxis should be considered for patients at high risk of FN.
Abstract
Purpose: The aim of this study was to evaluate the episodes of febrile neutropenia (FN) in patients with gastric cancer (GC),colorectal cancer (CRC), lung cancer (LC), and breast cancer (BC); and to identify the incidence and trends of admission rates, aswell as factors affecting mortality. Materials and Methods: Using nationwide claims data, all new admissions to hospitals for FN were selected. We evaluated theincidence of FN and mortality-related clinical factors in adult cancer patients who received cytotoxic chemotherapy from January2004 to December 2013. Results: While the incidence of FN increased, the length of hospitalization decreased in Korea. The incidence of FN was 19.8% inLC patients, 15.5% in GC patients, 13.3% in BC patients, and 9.5% in CRC patients. The overall in-hospital mortality of FN was12.9% and showed a decreasing trend. Admission rates to intensive care units and in-hospital mortality were the highest for lungcancer (15.2% and 19.3%, respectively). Age and sepsis syndrome were risk factors for in-hospital mortality for all cancer types. Conclusion: Careful observation and active prophylaxis should be considered for patients at high risk of FN.
참고문헌 (20)
- 홍세리, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2017", Cancer Research and Treatment, 52(2), pp.335~350 (2020), 대한암학회
- Freifeld AG, "Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer : 2010 update by the Infectious Diseases Society of America", Clin Infect Dis, 52, pp.e56~93 (2011)
- Dale DC, "Myelotoxicity and dose intensity of chemotherapy : reporting practices from randomized clinical trials", J Natl Compr Canc Netw, 1, pp.440~454 (2003)
- Schilling MB, "Costs and outcomes associated with hospitalized cancer patients with neutropenic complications : a retrospective study", Exp Ther Med, 2, pp.859~866 (2011)
- Caggiano V, "Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy", Cancer, 103, pp.1916~1924 (2005)
- Chindaprasirt J, "Mortality, length of stay, and cost associated with hospitalized adult cancer patients with febrile neutropenia", Asian Pac J Cancer Prev, 14, pp.1115~1119 (2013)
- Kozma CM, "Trends in neutropenia-related inpatient events", J Oncol Pract, 8, pp.149~155 (2012)
- Kuderer NM, "Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients", Cancer, 106, pp.2258~2266 (2006)
- Lingaratnam S, "The disease and economic burden of neutropenic fever in adult patients in Australian cancer treatment centres 2008 : analysis of the Victorian Admitted Episodes Dataset", Intern Med J, 41, pp.121~129 (2011)
- Lingaratnam S, "A cost analysis of febrile neutropenia management in Australia : ambulatory v. in-hospital treatment", Aust Health Rev, 35, pp.491~500 (2011)
- Schelenz S, "Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre", Ann Oncol, 23, pp.1889~1893 (2012)
- Wang XJ, "Economic burden of febrile neutropenia in solid tumor and lymphoma patients : an observational study in Singapore", Value in Health, 17, pp.A734~ (2014)
- Weycker D, "Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors", J Oncol Pract, 11, pp.47~54 (2015)
- Weycker D, "Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases", BMC Health Services Research, 13, pp.60~ (2013)
- Ihbe-Heffinger A, "Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer", Onkologie, 34, pp.241~246 (2011)
- André T, "Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer", N Engl J Med, 350, pp.2343~2351 (2004)
- Goldberg RM, "Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer : a North American Intergroup Trial", J Clin Oncol, 24, pp.3347~3353 (2006)
- Pinter T, "A phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim in patients receiving first-line FOLFOX", bevacizumab or FOLFIRI, Clin Colorectal Cancer, pp.2017, 16[DOI]
- Kalinka-Warzocha E, "Chemotherapy treatment patterns and neutropenia management in gastric cancer", Gastric Cancer, 18, pp.360~367 (2015)
- Dulisse B, "A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia", J Med Econ, 16, pp.720~735 (2013)